NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » pressreleases » Rockland Immunochemicals Donates 100% of “Pink” Product Proceeds to Breastcancer.org

Press
Release

Rockland Immunochemicals Donates 100% of “Pink” Product Proceeds to Breastcancer.org

Gilbertsville, PA. January 20th, 2014 – Rockland Immunochemicals Inc. today announced that it donated $6,700 to Breastcancer.org, based on the sales of “Pink products”. In October 2013, Rockland declared seven groups of products “pink” in an effort to support Breast Cancer Awareness Month. These product categories included a variety of conjugates, ATTO dyes and protein markers.

For over fifty years, Rockland has supported cancer research and contributed to treatments and findings, with the ongoing support of organizations such as Breastcancer.org. Antibodies are key components in all types of cancer research. Rockland has developed a number of multiassay validated conjugated and unconjugated polyclonal as well as monoclonal antibodies for cancer research, utilizing one of the most stringent quality control processes in the industry.

Rockland’s cancer related antibodies are designed to target specific proteins involved in a vast array of cancer pathways. Each antibody works uniquely and depends on the modification specific for the disease. Rockland’s products have been crucial in scientific contributions towards cancer research allowing numerous groundbreaking discoveries in the field.

Rockland uses its proven, robust antibody development technologies in combination with innovative screening techniques to develop clinically-relevant assays and biomarker tools. Currently, Rockland is in the process of developing an optimized and validated non-competitive immunoassay that will allow the user to quantify independently AKT isoform phosphorylation in a wide range of cancer cells. This assay can be applied to validate tumor models for breast, lung, and prostate cancers.

“We center a vast percentage of our state-of-the-art research around cancer, and feel that it is important to give back to organizations that focus on awareness and critical research.” says Jim Fendrick, President and CEO of Rockland Immunochemicals. “We are proud to donate the full proceeds from our pink campaign to help a cause so near and dear to us at Rockland.”


Pictured Above: Hope Wohl (CEO of Breastcancer.org), Rita Lusen
(Breastcancer.org), Maureen Fendrick (Breast cancer survivor), Terri Poole
(Rockland)

About Rockland Immunochemicals

Rockland Immunochemicals has supported the academic, biopharma and diagnostic
industries with antibodies and antibody based tools™ for basic research, assay
development and preclinical studies for over 50 years. With facilities in Pennsylvania,
Rockland manufactures over 10,000 products ideally suited for integration into
critical assays such as western blotting, immunohistochemistry (IHC),
immunofluorescence microscopy (IF), ELISA, ChIP and FLOW cytometry. Additional
information about Rockland’s Life Science Tools and Services can be found on the
company’s web site at www.rockland-inc.com.

About Breastcancer.org

Breastcancer.org, a nonprofit organization based in Ardmore, Pa, is dedicated to
providing the most reliable, complete, and up-to-date information about breast
health and breast cancer. Breastcancer.org’s mission is to help women and their
loved ones make sense of the complex medical and personal information about
breast cancer, so they can make the best decisions for their lives. For more
information, please visit www.breastcancer.org.

For additional information regarding this announcement, please contact:

Dana Dever
Marketing, Rockland Immunochemicals, Inc.
Phone: 610.369.1008
Email: dana.dever@rockland-inc.com

Contact